KYMR stock news
This page provides real-time market news, earnings updates, and company announcements related to Kymera Therapeutics, Inc. (KYMR).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-06-27 06:05 EST
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Finviz2026-02-24 12:03:54
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Finviz2026-02-26 12:03:47
Kymera Therapeutics, Inc. demonstrates strong financial strength
老虎证券2026-02-26 12:30:01
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), some existing shareholders of biotechnology company Kymera Therapeutics, Inc. plan to sell a total of 31.39 million shares of the company's common stock.
老虎证券2026-02-26 13:30:33
Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss
Finviz2026-03-10 02:42:44
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
Finviz2026-03-10 11:07:13
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
Finviz2026-03-10 11:07:13
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Finviz2026-03-28 15:03:55
Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
Finviz2026-04-09 11:03:39
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
Finviz2026-04-13 11:03:45
Kymera Therapeutics announced that patient enrollment has been completed for its mid-stage clinical trial targeting eczema.
老虎证券2026-06-25 12:10:08
On Friday, June 26, the U.S. Nasdaq Biotechnology Index closed up more than 2.2%, marking a record closing high for the fifth consecutive day.
华尔街见闻2026-06-26 23:16:24
Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss
Finviz2026-03-10 02:42:44
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
Finviz2026-03-10 11:07:13
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
Finviz2026-03-10 11:07:13
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Finviz2026-03-28 15:03:55
Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
Finviz2026-04-09 11:03:39
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
Finviz2026-04-13 11:03:45
Kymera Therapeutics announced that patient enrollment has been completed for its mid-stage clinical trial targeting eczema.
老虎证券2026-06-25 12:10:08
On Friday, June 26, the U.S. Nasdaq Biotechnology Index closed up more than 2.2%, marking a record closing high for the fifth consecutive day.
华尔街见闻2026-06-26 23:16:24
KYMR stock chart
KYMR stock detailsKYMR stock price change
On the last trading day, KYMR stock closed at 116.46 USD, with a price change of 16.61% for the day.
Trade spot stocks (24/7)Trade stock perps (up to 100x leverage)About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
To provide deeper liquidity, a more transparent trading experience, and greater capital efficiency, Bitget officially launched its all-new spot stock product, Bitget Stocks 2.0, on June 2, 2026.
The new product is independently issued by licensed RWA protocol Reality, with Bitget providing strategic support and asset security safeguards. This marks a major upgrade to the stock trading experience.
Bitget is moving stock trading beyond the limits of traditional trading models by fully integrating stock assets into its margin and yield ecosystem.
Learn more